Art

J-GLOBAL ID：201802274406243488   Reference number：18A1570660

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan

ニロチニブへの切替えはイマチニブでの分子遺伝学的大寛解を伴う慢性骨髄性白血病慢性期におけるより深い分子遺伝学的寛解と関連する:日本におけるSTAT1試験

Author (14)： NOGUCHI Shinsuke (Akita Univ. Graduate School of Medicine, Akita, JPN) ,  NAKASEKO Chiaki (International Univ. Health and Welfare School of Medicine, Narita, JPN) ,  NAKASEKO Chiaki (Chiba Univ. Hospital, Chiba, JPN) ,  NISHIWAKI Kaichi (Jikei Univ. Kashiwa Hospital, Kashiwa, JPN) ,  OGASAWARA Hitoshi (Odate Municipal Hospital, Odate, JPN) ,  OHISHI Kohshi (Mie Univ. Hospital, Tsu, JPN) ,  TOKUHIRA Michihide (Saitama Medical Univ., Kawagoe, JPN) ,  NOGUCHI Masaaki (Juntendo Univ. Urayasu Hospital, Urayasu, JPN) ,  KIMURA Hideo (Northern Fukushima Medical Center, Date, JPN) ,  HANDA Hiroshi (Gunma Univ. Hospital, Maebashi, JPN) ,  MITANI Kinuko (Dokkyo Medical Univ., Mibu-machi, JPN) ,  MIURA Masatomo (Akita Univ. Hospital, Akita, JPN) ,  WAKITA Hisashi (Japanese Red Cross Narita Hospital, Narita, JPN) ,  TAKAHASHI Naoto (Akita Univ. Graduate School of Medicine, Akita, JPN)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 108  Issue： 2  Page： 176-183  Publication year： Aug. 2018 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： より深い分子遺伝学的寛解 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1570660&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (2)： Imatinib ,  Nilotinib

Reference (26)：

• Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841-51.
• Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-203.
• Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044-54.
• Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124:729-36.
• Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17-23.

Terms in the title (10)： ニロチニブ ,  切替え ,  イマチニブ ,  分子遺伝学 ,  寛解 ,  慢性骨髄性白血病 ,  慢性期 ,  日本 ,  STAT1 ,  試験